Program
T10430
A development code. Also written as “T10430 lower dose”, “T10430 middle dose” and “T10430 higher dose”.
Its studies are mostly in Myopia, led by Laboratoires Thea.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Laboratoires Thea | 11 open or running | phase 2since Mar 25, 2026 | Mar 25, 2026 | Nov 2027phase 2 · NCT07522242 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 25, 2026First study: phase 2 study in MyopiaFirst studyNCT07522242 · 200 planned · Jordan, South Africa, Tunisia
Ahead
- Nov 2027Primary completion: phase 2 study in MyopiaNCT07522242
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07522242Myopia · Jordan, South Africa, Tunisia | 2 | Recruiting | Nov 2027 | 200 |
How it is read
Names in the registry
- “T10430 lower dose”, 1 entry
- “T10430 middle dose”, 1 entry
- “T10430 higher dose”, 1 entry
Codes read as this program: T10430.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.